Crossject partners with Xi'an Xintong Pharmaceutical Research
Wednesday, December 09, 2015
Crossject SA announces partnership agreement for Zeneo Methotrexate in China with Xi'an Xintong Pharmaceutical Research.
Non-exclusive agreement includes milestone payment of 3 million euros ($3.3 million) at marketing authorization.
Non-exclusive agreement includes payment of royalties representing 25 pct of sales.
Non-exclusive agreement includes mid-term sales commitments of 58 million euros for this product in year three after market approval.
Marketing authorization filing in China is expected in early 2017.
reuters.com
